WallStreetZenWallStreetZen

NASDAQ: ANIP
Ani Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ANIP past earnings growth

How has ANIP's earnings growth performed historically?
Company
N/A
Industry
13.17%
Market
62.15%
ANIP's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ANIP's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

ANIP past revenue growth

How has ANIP's revenue growth performed historically?
Company
53.87%
Industry
10.21%
Market
17.33%
ANIP's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ANIP's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ANIP's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ANIP earnings and revenue history

Current Revenue
$486.8M
Current Earnings
$17.2M
Current Profit Margin
3.5%

ANIP Return on Equity

Current Company
4.3%
Current Industry
15.4%
Current Market
188%
ANIP's Return on Equity (4.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ANIP announces earnings.

ANIP Return on Assets

Current Company
2%
Current Industry
3.4%
ANIP is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ANIP Return on Capital Employed

Current Company
6.17%
Current Industry
5.1%
ANIP has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ANIP vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ANIP$486.82M$107.87M$17.15M+19.28%-8.07%
TLRY$743.25M-$186.62M-$351.95M+30.54%N/A
IRWD$442.74M-$895.55M-$1.00B+5.02%N/A
DVAX$232.28M$9.67M-$6.39M+95.19%N/A
PCRX$674.98M$157.58M$41.96M+14.88%-90.17%
View Top Pharmaceutical Stocks

ANIP earnings dates

Next earnings date
May 10, 2024

Ani Pharmaceuticals Earnings & Revenue FAQ

What were ANIP's earnings last quarter?

On Invalid Date, Ani Pharmaceuticals (NASDAQ: ANIP) reported Q4 2023 earnings per share (EPS) of $0.02, up 106.9% year over year. Total Ani Pharmaceuticals earnings for the quarter were $749.00 thousand. In the same quarter last year, Ani Pharmaceuticals's earnings per share (EPS) was -$0.29.

If you're new to stock investing, here's how to buy Ani Pharmaceuticals stock.

What was ANIP's earnings growth in the past year?

As of Q2 2024, Ani Pharmaceuticals's earnings has grown year over year. Ani Pharmaceuticals's earnings in the past year totalled $17.15 million.

What is ANIP's earnings date?

Ani Pharmaceuticals's earnings date is Invalid Date. Add ANIP to your watchlist to be reminded of ANIP's next earnings announcement.

What was ANIP's revenue last quarter?

On Invalid Date, Ani Pharmaceuticals (NASDAQ: ANIP) reported Q4 2023 revenue of $131.65 million up 39.71% year over year. In the same quarter last year, Ani Pharmaceuticals's revenue was $94.23 million.

What was ANIP's revenue growth in the past year?

As of Q2 2024, Ani Pharmaceuticals's revenue has grown 53.87% year over year. This is 43.66 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.21%. Ani Pharmaceuticals's revenue in the past year totalled $486.82 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.